Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Biochemical Pharmacology Discussion Group

Understanding drug action at the frontiers of modern drug design


Developing effective new drugs relies upon a deep understanding of how these chemical compounds act in isolation and in the context of the multi-faceted systems within the human body.

The Biochemical Pharmacology Discussion Group advances our fundamental knowledge of the activity and metabolism of both small molecules and biologics at the biochemical and molecular levels. Research spans chemotherapy, neuropharmacology, antimicrobials, inflammation, and immunopharmacology, as well as gastrointestinal, cardiovascular, and endocrine pharmacology and toxicology.

The group also serves as the Biochemical Topical Group for the American Chemical Society's New York Chapter.

Did you know it takes an average of 12 years for a drug to travel from lab to patient? Research and development of a single successful drug costs an estimated $2.6 billion.


Sonya Dougal, PhD


Steering Committee Members

The Biochemical Pharmacology Discussion Group Steering Committee, composed of multi-sector and multi-institutional scientists from the Academy’s network, provides thought leadership on key issues of interest to the biochemistry, molecular biology, biomedical research, translational medicine, and related communities, helping to inform and shape our program portfolio.
Lynn M. Abell, PhD
Lynn M. Abell, PhD

Kojin Therapeutics

Magdalena Alonso-Galicia, PhD

Roivant Sciences

Joshua Apgar, PhD

Applied BioMath

Mercedes Beyna, MS
Mercedes Beyna, MS


Scott Brodeur, PhD
Scott Brodeur, PhD

Janssen Research and Development

Megan Dow, PhD
Megan Dow, PhD

Biohaven Pharmaceuticals

Steven Gross, PhD

Weill Cornell Medical College

John Hambor, PhD

Boehringer Ingelheim

Julia Heinrich, PhD

Bristol-Myers Squibb

Andres Hurtado-Lorenzo, PhD
Andres Hurtado-Lorenzo, PhD

Crohn’s & Colitis Foundation

Katalin Kauser, MD, PhD, DSc


Christine Grimaldi, PhD
Christine Grimaldi, PhD

Boehringer Ingelheim

Scott MacDonnell, PhD

Regeneron Pharmaceuticals, Inc.

Marco Prunotto, PhD


Claire M. Steppan, PhD
Claire M. Steppan, PhD


George Zavoico, PhD

Cue Biopharma